CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 21, 2018--
announced today that JC Gutiérrez-Ramos, Ph.D., Synlogic’s president and
chief executive officer, will present a corporate update at the 17th
Annual Needham Healthcare Conference at 12:15 p.m. ET on Wednesday,
March 28, 2018, in New York City.
A live webcast of the presentation can be accessed under “Event
Calendar” in the Investors & Media section of the Company’s website.
An archived webcast recording will be available on the Synlogic website
for approximately 30 days after the event.
Synlogic is pioneering the development of a
novel class of living treatments, Synthetic Biotic™ medicines, based on
its proprietary drug development platform. Synlogic’s initial pipeline
includes Synthetic Biotic medicines for the treatment of rare genetic
diseases, such as Urea Cycle Disorder (UCD) and Phenylketonuria (PKU).
In addition, the company is leveraging the broad potential of its
platform to create Synthetic Biotic medicines for the treatment of more
common diseases, including liver disease, inflammatory and immune
disorders, and cancer. Synlogic is collaborating with AbbVie to develop
Synthetic Biotic-based treatments for inflammatory bowel disease (IBD).
For more information, please visit www.synlogictx.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180321006070/en/
Elizabeth Wolffe, Ph.D., 617-207-5509